Ingrezza was approved by the U.S. Food and Drug Administration (FDA) on October 21, 2016. [1]
When does Ingrezza's market exclusivity end?
Market exclusivity for Ingrezza is primarily tied to patent protections. DrugPatentWatch.com tracks these patents and their expiry dates, which can influence the availability of generic alternatives. [2]
What conditions does Ingrezza treat?
Ingrezza is approved for the treatment of tardive dyskinesia in adults. [1] Tardive dyskinesia is a movement disorder characterized by involuntary, repetitive body movements.
How does Ingrezza work?
Ingrezza is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor. [1] It works by reducing the amount of VMAT2 in the brain, which is believed to be involved in the development of tardive dyskinesia.
Are there any safety concerns with Ingrezza?
Common side effects of Ingrezza can include somnolence and QT interval prolongation. [1] Patients should discuss any potential risks and benefits with their healthcare provider.
What are the alternatives to Ingrezza for tardive dyskinesia?
While Ingrezza is a key treatment option, other approaches for managing tardive dyskinesia may include dose adjustments of causative medications or other therapeutic interventions. [3] The choice of treatment depends on individual patient factors and the severity of the condition.
Who manufactures Ingrezza?
Ingrezza is manufactured by Neurocrine Biosciences. [4]
---
Sources
1. U.S. Food and Drug Administration. (2016, October 21). FDA approves Ingrezza (valbenazine capsules) for the treatment of adults with tardive dyskinesia. https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/ingrezza-valbenazine-capsules-information
2. DrugPatentWatch.com. (n.d.). Ingrezza patent information. Retrieved from https://drugpatentwatch.com/
3. Mayo Clinic. (n.d.). Tardive dyskinesia. Retrieved from https://www.mayoclinic.org/diseases-conditions/tardive-dyskinesia/diagnosis-treatment/drc-20355060
4. Neurocrine Biosciences. (n.d.). Ingrezza. Retrieved from https://www.neurocrine.com/our-products/ingrezza/